283
Views
2
CrossRef citations to date
0
Altmetric
Articles

Higher adalimumab serum levels do not increase the risk of adverse events in patients with inflammatory bowel disease

, ORCID Icon &
Pages 712-717 | Received 03 Apr 2019, Accepted 15 May 2019, Published online: 30 May 2019
 

Abstract

Background: The relationship between serum adalimumab concentrations and adverse events in patients with inflammatory bowel disease (IBD) is unknown. We aimed to determine whether patients with IBD using adalimumab are at increased risk of adverse events if they have higher adalimumab serum levels compared to those with lower adalimumab levels.

Methods: This was a retrospective study of 191 IBD patients with at least one serum adalimumab level measurement available. The cohort was divided using a cutoff level of 10 mcg/mL. The primary outcome was the rate of overall adverse events between the two groups. Secondary outcomes included rate of infections, dermatologic reactions, injection-site reactions and other adverse events in both groups. Rates of discontinuation of adalimumab due to adverse events were evaluated. Multivariate logistic regression analysis was performed to evaluate the relationship between adalimumab levels and adverse events.

Results: A total of 41 adverse events were reported in 191 patients in the overall cohort. Among 86 patients with higher adalimumab levels, 22 adverse events were reported, vs. 19 adverse events among 105 patients with lower adalimumab levels (25.6% vs. 18.1%, p = .21). Analysis according to adalimumab level tertiles also did not show significant differences in the rates of adverse events. A multivariate forward selection model also did not find higher odds of an adverse event in IBD patients with higher adalimumab levels compared to lower levels (OR 1.54, 95% CI 0.77–3.08).

Conclusions: There does not appear to be a relationship between adalimumab exposure and risk of adverse events in IBD patients.

Disclosure statement

Dr. Neeraj Narula holds a McMaster University Department of Medicine Internal Career Award. Dr. Neeraj Narula has received honoraria from Janssen, Abbvie, Takeda, Pfizer, Merck and Ferring. John K. Marshall has received honoraria from Janssen, AbbVie, Aptalis, Astra-Zeneca, Ferring, Forest, Optimer, Procter & Gamble, Shire, Takeda and Warner-Chilcott. No other authors had any conflicts of interest to declare with regards to this manuscript.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.